Press Releases

02.22.2023
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
02.16.2023
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
02.02.2023
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01.04.2023
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01.03.2023
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
12.20.2022
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
12.02.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.30.2022
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
11.30.2022
Iveric Bio Announces Proposed Offering of Common Stock
11.17.2022
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy